Icahn School Of Medicine At Mount Sinai

Stereotactic body radiation therapy followed by sorafenib extended survival compared with sorafenib alone among patients with hepatocellular carcinoma, according to study results presented at ASCO Gastrointestinal Cancers Symposium.

An artificial intelligence-derived marker using electronic health records noninvasively quantified plaque burden and mortality risk for adults from two large biobank cohorts, offering an option for more targeted CAD diagnosis, data show.

Pelabresib plus ruxolitinib conferred benefit to Janus kinase inhibitor-naive patients with myelofibrosis, according to study results presented at ASH Annual Meeting and Exhibition.

Spaceflight may place astronauts at increased risk for developing mutations that can lead to cancer and heart disease, according to a study published in Nature Communications Biology.

NEW ORLEANS — Nearly three-quarters of patients who received talquetamab for relapsed or refractory multiple myeloma had an objective response to therapy, results of the phase 1/phase 2 MonumenTAL-1 trial showed.

Compared with outpatient hospitals, ASCs reduced total health care utilization and expenditures for ACL reconstruction in the United States from 2013 to 2017, according to published results.

In a real-world setting, a next-generation self-expanding transcatheter aortic valve replacement system showed improved commissural alignment and target implant depth compared with a prior system, researchers reported at PCR London Valves.

Despite data on the approach still being accumulated, a panel of experts at Chemotherapy Foundation Symposium predicted that chimeric antigen receptor T cells will become front-line therapy for multiple hematologic malignancies.

John O. Mascarenhas, MD, spoke with Healio about takeaways from a presentation examining ways to optimize the currently available JAK2 inhibitors for the treatment of myelofibrosis.

In this video, John O. Mascarenhas, MD, provided an overview of his presentation at 14th International Congress on Myeloproliferative Neoplasms that delved into new treatments, specifically focused on myelofibrosis.